UNITED STATES: Gilead Sues Teva over HIV Drug Patent

Important note: Information in this article was accurate in 2008. The state of the art may have changed since the publication date.

UNITED STATES: Gilead Sues Teva over HIV Drug Patent

Business Week (12.15.08) - Tuesday, December 16, 2008

The biotechnology firm Gilead Sciences Inc. on Friday said it has filed a suit to block Isreal-based Teva Pharmaceutical Industries Ltd. from making a generic version of the AIDS drug Truvada (emtricitabine and tenofovir). In November, Teva asked the Food and Drug Administration to approve its generic copy of Truvada, claiming two of 10 patents covering Gilead's brand-name drug are invalid, unenforceable or would not be infringed by the generic. Both patents relate to emtricitabine, and Gilead claims they do not expire until 2021. The lawsuit, filed at the US District Court in New York, stops the FDA approval process for up to 30 months or until a court rules on the suit's validity.
081216
AD082356

Copyright © 2008 - Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Elton John AIDS Foundation, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.

Always watch for outdated information. This article first appeared in 2008. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2008. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.